Shares of Synairgen Plc, a tiny pharmaceutical firm born out of a U.K. university, soared as much as 373% after the company said its experimental drug cut the risk of developing the worst symptoms of Covid-19.
In a clinical trial involving 220 subjects, the probability of a patient requiring ventilation or dying dropped 79% for those who got Synairgen’s SNG001 versus those who received a placebo, the Southampton, England-based company said in a statement. Those receiving SNG001 also were more than twice as likely to fully recover from the illness, it added.
The inhaled product is a formulation of a naturally occurring protein, known as interferon beta, that Synairgen has previously said may be deficient in those with greater susceptibility to the new coronavirus, such as the elderly or those with heart and lung complications or diabetes.
Synairgen rose 332% to 157.50 pence at 10:10 a.m. London time. The stock’s latest surge takes its year-to-date gain to about 2,581%, giving Synairgen, which trades on London’s AIM venue for growth companies, a market capitalization of about 235.4 million pounds ($296 million).
Subscribe to The Capsule, a daily brief monitoring advances in health care and biopharma, delivered free to your inbox.
“Valuing the Covid-19 opportunity is nigh on impossible,” FinnCap analyst Mark Brewer said in a note to clients, adding that upcoming discussions with regulators should clarify SNG001’s route to market. Finncap is also corporate broker to the company.
Synairgen, founded by three professors from the University of Southampton, previously partnered with AstraZeneca Plc in 2014 to study SNG001 in severe asthma, but the trial was halted two years later after an interim analysis showed a very low number of reported severe exacerbations, making it difficult to draw conclusions.
More must-read international coverage from Fortune:
- What U.S. companies should consider following the bombshell EU Privacy Shield ruling
- The downfall of Wirecard is stirring an epic shareholder revolt in Germany
- “A real bind”: Banks that carry out Trump’s new sanctions could violate Hong Kong security law
- The one element of Hong Kong’s new security law that concerns business the most
- Wirecard shows auditing is broken. Here’s why—and how to fix it